Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)

Bibliographic Details
Main Author:	Ankit Misra
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2021;volume=37;issue=3;spage=291;epage=292;aulast=Misra

Similar Items

Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer
by: D.E. Magee, et al.
Published: (2020-07-01)

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy
by: A. Bamias, et al.
Published: (2020-11-01)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
by: Enrique Grande, et al.
Published: (2023-12-01)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
by: Xiaoyan Liu, et al.
Published: (2022-08-01)

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
by: Mencinger Marina, et al.
Published: (2021-05-01)

Real-life data of Atezolizumab in urothelial carcinoma, second-line metastatic disease
by: L.F. Sánchez-Cousido, et al.
Published: (2020-11-01)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
by: Furubayashi N, et al.
Published: (2020-10-01)

The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
by: Husam A. Alqaisi, et al.
Published: (2022-04-01)

Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab
by: Patrik Palacka, et al.
Published: (2022-07-01)

Impact of FGFR3 genomic aberrations in patients with metastatic urothelial carcinoma treated with first line platinum-based chemotherapy
by: R. Morales Barrera, et al.
Published: (2020-07-01)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
by: Hideaki Uchida, et al.
Published: (2023-05-01)

Trends in the utilizaton of platinum-based neoadjuvant chemotherapy for upper tract urothelial carcinoma
by: H. Horiguchi, et al.
Published: (2020-07-01)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
by: Maria Alice Franzoi
Published: (2020-12-01)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
by: Joohyun Hong, et al.
Published: (2022-08-01)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
by: Loïg Gaugain, et al.
Published: (2023-01-01)

Nimotuzumab plus platinum-based chemotherapy platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
by: Yunshu Zhu, et al.
Published: (2020-09-01)

Metastatic urothelial carcinoma
by: Elisabeth Gómez-Moyano, et al.
Published: (2021-08-01)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
by: Tassinari E, et al.
Published: (2022-06-01)

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
by: Alexander S Baras, et al.
Published: (2015-01-01)

The use of atezolizumab in combination with chemotherapy in first-line of metastatic small cell lung cancer. Case report
by: Nikolai A. Ognerubov, et al.
Published: (2021-08-01)

Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
by: Zsófia Küronya, et al.
Published: (2022-10-01)

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
by: Alexander S Baras, et al.
Published: (2015-01-01)

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
by: Jeffrey J. Wallin, et al.
Published: (2016-08-01)

Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
by: WEI Zongjie, et al.
Published: (2022-07-01)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
by: Akito Fukuda, et al.
Published: (2022-01-01)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
by: Fischer C, et al.
Published: (2020-06-01)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
by: Anifat A. Elegbede, MSc, MbChB, et al.
Published: (2021-12-01)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
by: Yujing Xin, et al.
Published: (2022-08-01)

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
by: Alejandra Bernardini, et al.
Published: (2022-01-01)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021-10-01)

Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice
by: Richard Cathomas, et al.
Published: (2020-05-01)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma
by: Andrew B. Katims, et al.
Published: (2022-11-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Metastatic urothelial carcinoma presenting as acute cholecystitis
by: Xing Yao Ling, et al.
Published: (2019-01-01)

Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab
by: Yasunori Akashi, et al.
Published: (2023-12-01)

Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy naïve patients with metastatic urothelial carcinoma
by: Jan Slopovsky, et al.
Published: (2021-01-01)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
by: Hong-Chen Qu, et al.
Published: (2020-01-01)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
by: Naiki T, et al.
Published: (2018-09-01)

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
by: Mohammad Jad Moussa, et al.
Published: (2024-02-01)

602 A phase I trial of atezolizumab and varlilumab in combination with radiation in patients with metastatic non-small cell lung cancer (NSCLC)
by: Yong Lin, et al.
Published: (2023-11-01)